Inactivation of the peroxisomal ABCD2 transporter in the mouse leads to late-onset ataxia involving mitochondria, Golgi and endoplasmic reticulum damage

Isidre Ferrer¹, Josef P. Kapfhammer², Colette Hindelang³, Stephan Kemp⁴, Nathalie Troffer-Charlier³, Vania Broccoli⁵, Noëlle Callyzot⁶,⁷, Petra Mooyer⁴, Jacqueline Selhorst³,⁴, Peter Vreken⁴, Ronald J.A. Wanders⁴, Jean Louis Mandel³ and Aurora Pujol⁷,*

¹Institut de Neuropatologia, Hospital Universitari de Bellvitge, Departament de Biologia Cel.lular i Anatomia Patològica, Facultat de Medicina, Universitat de Barcelona, IDIBELL c/Feixa Llarga s/n E-08907 L’Hospitalet de Llobregat, Barcelona, Spain, ²Anatomisches Institut, Universität Basel, Pestalozzistr. 20, CH-4056 Basel, Switzerland, ³Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP and Collège de France, B.P. 10142, 67404 Illkirch Cedex, C.U. de Strasbourg, France, ⁴Laboratory of Genetic Metabolic Diseases, Department of Clinical Chemistry and Department of Pediatrics, Emma Children’s Hospital, Academic Medical Center, University of Amsterdam, PO Box 22700, 1100 DE Amsterdam, The Netherlands, ⁵Stem Cell Research Institute, DIBIT, San Raffaele Science Park, Via Olgettina 58, Milan, Italy, ⁶Société Neurofit, SA 67404 Illkirch Cedex, C.U. de Strasbourg, France and ⁷Institución Catalana de Recerca i Estudis Aplicats (ICREA) and Centre de Genètica Mèdica i Molecular, IRO/IDIBELL, Gran Via s/n, km 2.7, 08907 L’Hospitalet de Llobregat, Barcelona, Spain

Received July 12, 2005; Revised and Accepted October 6, 2005

ATP-binding cassette (ABC) transporters facilitate unidirectional translocation of chemically diverse substances, ranging from peptides to lipids, across cell or organelle membranes. In peroxisomes, a subfamily of four ABC transporters (ABCD1 to ABCD4) has been related to fatty acid transport, because patients with mutations in ABCD1 (ALD gene) suffer from X-linked adrenoleukodystrophy (X-ALD), a disease characterized by an accumulation of very-long-chain fatty acids (VLCFAs). Inactivation in the mouse of the abcd1 gene leads to a late-onset neurodegenerative condition, comparable to the late-onset form of X-ALD [Pujol, A., Hindelang, C., Callizot, N., Bartsch, U., Schachner, M. and Mandel, J.L. (2002) Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum. Mol. Genet., 11, 499–505]. In the present work, we have generated and characterized a mouse deficient for abcd2, the closest paralog to abcd1. The main pathological feature in abcd2−/− mice is a late-onset cerebellar and sensory ataxia, with loss of cerebellar Purkinje cells and dorsal root ganglia cell degeneration, correlating with accumulation of VLCFAs in the latter cellular population. Axonal degeneration was present in dorsal and ventral columns in spinal cord. We have identified mitochondrial, Golgi and endoplasmic reticulum damage as the underlying pathological mechanism, thus providing evidence of a disturbed organelle cross-talk, which may be at the origin of the pathological cascade.

*To whom correspondence should be addressed at: CGMM, IRO/IDIBELL, Hospital Duran i Reynals, Gran Via s/n, km 2.7, 08907 L’Hospitalet de Llobregat, Barcelona, Spain. Tel: +34 932607425; Fax: +34 932607414; Email: apujol@iro.es


© The Author 2005. Published by Oxford University Press. All rights reserved.
For Permissions, please email: journals.permissions@oxfordjournals.org
INTRODUCTION

Peroxisomes are subcellular organelles present in most eukaryotic cells (1). They fulfill a number of essential cellular functions, including the catalysis of piopecol, phytycan and very-long-chain fatty acids (VLCFAs) and the biosynthesis of plasmalogeners (ether lipids) and bile acids (2). The importance of peroxisomes for normal cellular functioning is illustrated by the peroxisome biogenesis disorders (PBD) (Zellweger syndrome, neonatal adrenoleukodystrophy and infantile Refsum’s disease). PBDs are characterized by a loss of functional peroxisomes, resulting in the presence of matrix enzymes in the cytosol because of mutations in one of the many so-called PEX genes, which encode proteins (peroxins) essential for proper peroxisome biogenesis (3,4). In Zellweger syndrome, the most severe of these disorders, infants exhibit neonatal hypotonia, hepatic dysfunction and seizures associated with neuronal migration defects (McKusick 214100). Indeed, in the nervous system, peroxisomes have been localized in cell bodies, axons, dendrites, neurites and presynaptic axon terminals (5–8) and active growth cones (9), suggesting an active metabolic role for peroxisomes in guidance cues, in outgrowth and in maintenance of neurites.

ATP-binding cassette (ABC) transporters constitute a family of transport proteins that couple the energy of ATP hydrolysis to the translocation of a wide variety of substrates, such as ions, proteins, sugars, amino acids and lipids, across biological membranes (10,11). In peroxisomes, four genes coding for ABC transporters have been identified (ABCD1 to ABCD4). Mutations in ABCD1 results in X-linked adrenoleukodystrophy/adrenomyeloneuropathy (X-ALD/AMN) (12). To date, no human disease has been attributed to defects in the genes coding for ALDRP (ABCD2), PMP70 (ABCD3) or PMP69 (ABCD4). Patients with X-ALD are characterized biochemically by elevated levels of VLCFAs because of a defect in peroxisomal β-oxidation of VLCFAs. Because of the biochemical phenotype of X-ALD patients, it has been postulated that the product of the ABCD1 gene, i.e. ALDP, may import VLCFAs into the peroxisome. This is supported by the observation that yeast lacking one or both of the two yeast ABCD transporters (Pxa1p and Pxa2p) have elevated VLCFA levels (13,14). The functions of the three other transporters in higher eukaryotes are unknown, but their sequence homology (88% for ABCD1 and ABCD2; 66% for ABCD1 and ABCD3 or ABCD4) indicate that they might exert related or overlapping function(s) in peroxisomal fatty acid metabolism. For instance, PMP70 and ALDRP have been shown to compensate for the loss of ALDP when overexpressed in vitro (15,16). However, the intrinsic function of PMP70 as evaluated in Pmp70−/− mice, has recently been reported to be related to the catabolism of middle- and branched-chain fatty acids (pristanic and phytanic), in the absence of VLCFAs accumulation (17). Similarly, inactivation of abcd2 does not lead to accumulation of VLCFAs in nervous tissues, although its stable overexpression by transgenesis in the ALD knock-out mouse prevents accumulation of VLCFAs as well as the onset of neurological phenotype (18), which indicates that ALDRP is indeed able to take over from ALDP, at least when overexpressed. In the present study, we set up to explore in-depth the intrinsic role of ALDR.
Expression pattern of abcd1 and abcd2 genes

We have shown in a previous study that the expression of both transporters was mirror-like or complementary in adrenal gland and testis. In the brain, abcd2 mRNA was detected mainly in pyramidal and granular cell layers of dentate gyrus and cerebral cortex. The inner granular and Purkinje cell layers in cerebellum were also strongly labeled for abcd2. In contrast, abcd1 expression was essentially restricted to glial and endothelial cells (19). Here, we aimed at refining abcd2 mRNA expression pattern during embryonic life and in early adulthood (Fig. 2).

Abcd2 appears well expressed in dorsal root ganglia (DRG) (sensitive peripheral neurons) in early embryonic stages (E11 and 5) (Fig. 2A) and in proliferative neuronal layers from cerebral cortex and neuro-olfactory epithelium at mid-embryonic stages (Fig. 2C, E and F, at E14 and 5). In adult spinal cord and pons, motor neurons, interneurons and basal ganglia are strongly positive for abcd2 (Fig. 2G and H). In summary, abcd2 is widely expressed in different types of neuronal populations, from embryonic sensitive neurons of DRGs to mature differentiated spinal motor neurons. In contrast, abcd1 exhibited a low and ubiquitous expression pattern throughout development into adulthood, without being excluded from neurons.

Behavioral deficits in ALDRP-deficient mice

To assess the neurological consequences of ALDRP/ABCD2 absence, mutant animals were analyzed using a variety of motor skills and behavioral tests. Although no overt clinical phenotype was observed at 6 months, mice lacking ALDRP displayed progressive behavioral deficits, consistent with ongoing neural degeneration from 12 months onwards. The most striking abnormalities were found in the areas of balance, coordination and reflexes. The rotarod test was used as a measure of motor balance, coordination and control. When compared with wild-type littersates at 12 months of age, abcd2−/− mice displayed a marked impairment in their performance during 4 days trial on the rotating rod set at an accelerating speed (P < 0.01 by ANOVA) (Fig. 3B). Abcd1-mice performed similar to their wild-type littersmates at this age (data not shown). Latter in life, around 20 months, cohorts of mice from all genotypes were again challenged. The performance of abcd2 null mice was even more impaired, and a slight whole body tremor suggestive of cerebellar involvement was apparent in three out of 14 abcd2−/− mice and in eight out of 11 abcd1−/abcd2−/− double mutant mice. Data are in agreement with the rotarod experiments reported in a former study (18) (data not shown).

We studied spontaneous locomotion and exploratory behavior in the open field at 12 months of age. Surprisingly, despite their impaired performance in rotarod tests, abcd2−/− null mice were significantly more active than their wild-type littersmates. This was especially apparent after the first 5-min period (Fig. 3A). This finding is indicative of a lack of habituation capacity to a new environment. Interestingly, abcd1 knock-out mice and particularly double mutants exhibited a
Figure 3. Aldr−/− mice present a progressive neurological phenotype. (A) Open-field experiments showing lack of habituation of aldr−/− mutants at 12 months of age (n = 8 wt and n = 12 aldr−/−). (B) Rotarod analysis of mutants versus control littermates, same age (C and D, bar cross test). (C) The time spent to cross the bar. Aldr−/− slipped away more often than their wild-type littermates and ald-mice. Double mutant animals show delayed time to cross the bar and increased number of slips. (E) Electromyographical measurements of the spinal somatosensory evoked response (H-wave or reflex wave) in aldr−/−, ald− and double mutant versus control littermates at 12 and 20 months of age. The absence of H-wave is aldr dependent. (F) Capacity of adult fibroblasts to β-oxidize C26:0, expressed as picomoles per hour per milligram of protein. Wild-type levels have been set to 100. Ald− and double mutant fibroblasts show similar reduction to 60% of the wild-type level (P < 0.0008). (G and H) Quantification of saturated VLCFA levels by ESI-MS in adult fibroblasts and DRG samples, expressed as micromoles per milligram of protein. Wild-type levels have been set to 100. (Single asterisk) Significant difference versus wild-type. (Double asterisks) Significant difference versus ald− samples (when ald− is different against wild-type). All statistics by ANOVA (Statview Package 5, significance set at P < 0.01).
deficits in amplitude and latency parameters to abcd2 types even at older ages. Double mutants exhibit comparable response or spinal reflex (H-wave amplitude). At 12 months of age, the time required for mice to reach a platform along a balance bar was significantly increased in abcd1/abcd2−/− double mutants (P < 0.001) (Fig. 3C). Both abcd2−/− and abcd1−/abcd2−/− mice exhibited a marked tendency to slip off the bar, a sign of ataxia (Fig. 3D), and often failed to maintain balance and fell. Instead of walking and maintaining a stable upright posture, they displayed ventral recumbence, with their entire body flattened against the surface of the bar, and their hind and fore limbs wrapped laterally around the bar. They used their fore limbs to drag themselves along the beam, being their hind limbs generally not used. This sign was particularly evident in double mutant mice. At 20 months of age, six out of 11 double mutant mice were not able to perform the test, because they “froze” or fell repeatedly from the bar (data not shown). These subsets of mice that showed a more severe phenotype exhibited, in addition, exaggerated bilateral extension of fore and hind limbs when suspended by their tails. We detected postural hypotonia, characterized by animals lying flat on their abdomens with fore and hind limbs splayed laterally. Because this effect could be caused by inhibition of postural muscle tone (20), we measured muscular strength with a dynamometer. No difference could be demonstrated between mutants and controls (data not shown), thus excluding any gross influence of muscle weakness on their rotarod or bar cross performance.

Defective spinal reflex in abcd2−/− mice

We assessed function of the peripheral nervous system by electromyographical exploration after somatosensory stimulation of the sciatic nerve. ALDP deficient mice present altered motor and sensitive conduction velocities (21). These deficits were not found in abcd2 mutants. Here, we investigated an additional parameter, the spinal somatosensory response or spinal reflex (H-wave amplitude). At 12 months of age, abcd2−/− mice present lower amplitude of the H-wave than their wild-type littermates (Fig. 3E). Latency of the H-wave is normal at that age, but diminishes with age (Fig. 3E). In contrast, this loss of spinal reflex is not presented by abcd1 mutants, which have values comparable to wild-types even at older ages. Double mutants exhibit comparable deficits in amplitude and latency parameters to abcd2−/− mice. These results indicate that the large proprioceptive sensory neurons at DRG or their afferents are functionally defective and are consistent with ataxia and loss of proprioception evidenced at the bar cross and rotarod tests.

Biochemical function of ALDRP

Given the high sequence homology and the differential expression pattern of both proteins, we speculated that ALDP and ALDRP could play similar or overlapping biochemical functions in different cell types. Indeed, upon overexpression, ALDRP has been shown to compensate for ALDP loss in vitro and in vivo. In X-ALD patient fibroblasts, transient overexpression of ALDR cDNA corrects the biochemical defect and transgenic overexpression of ALDRP in abcd1-mice prevents the VLCFAs accumulation in target tissues (18). However, saturated VLCFAs do not accumulate in adult brain, spinal cord and sciatic nerve of abcd2−/− mice (18). Here, we have investigated saturated VLCFA levels and C26:0 β-oxidation capacity on adult fibroblasts derived from our different mouse mutants. In this cell type, lack of ALDRP is neither translated into an accumulation of VLCFAs nor into a decrease of C26:0 β-oxidation capacity (Fig. 3G and H). Interestingly, double mutant fibroblasts accumulate higher levels of C26:0 than abcd1-fibroblasts (P < 0.001). In addition, C24:0 levels are higher in double mutants than in wild-type or abcd1-fibroblasts (P < 0.01). This suggests that abcd2 might cooperate or compensate to some extent for abcd1 loss of function. This functional compensation does not occur through of an increase of abcd2 expression at the mRNA or protein levels (data not shown).

Seeking for an alternative consequence of ALDRP loss of function different from VLCFAs accumulation, we set out to determine levels of other peroxisomal metabolites. We quantified phytic acid and pristanic acids in plasma and liver and the plasmalogens C16:0 DMA and C18:0 DMA in red blood cells. We also quantified levels of monounsaturated fatty acids from the ω9 series (C16:1, C18:1, C20:1, C22:1, C24:1) and polyunsaturated long-chain fatty acids from the ω3(C18:3, C18:4, C20:5, C22:5, C22:6), ω6 (C18:2, C18:3, C20:2, C20:3, C20:4, C22:2, C22:4, C22:5) and ω7 (C16:1, C18:1, C20:1) series in brain and plasma. We could not evidence any significant difference between abcd2−/− and their wild-type littermates (data not shown).

The high expression levels of ALDRP in DRG and the defective spinal reflex of abcd2−/− highlight this particular cell population as a target to identify a biochemical phenotype (90% of the cells in DRGs are neuronal bodies). We dissected DRGs from 5- to 6-day-old pups of abcd2−/− and wild-type littermates and quantified VLCFAs. We could indeed detect an accumulation of C26:0 in DRGs from abcd2−/− mice (Fig. 3I and J, P < 0.002). For comparison, we also analyzed DRGs from abcd1−/− and abcd1/abcd2−/− double mutants. Double mutants showed similar VLCFA levels than abcd2−/− mice. DRGs of abcd1−/− animals also showed slightly increased levels of C26:0, however, without reaching statistical significance. Thus, in DRGs, abcd2 seems to play the same role regarding C26:0 import/catabolism that abcd1 does not.

Peripheral and central pathologies are associated with the neurological phenotype

Analysis of DRG cell number and size from semi-thin sections did not yield a significant difference between the abcd2−/− mice and their wild-type littermates either at 12 or 20 months of age (data not shown). However, electron microscopy examination revealed a specific pattern of degeneration, more evident at 20 months of age. Both in satellite cells and ganglia neurons, the accumulation of residual and zebra-like bodies was prominent (Fig. 4A). A significant number of mitochondria showed degenerative images and contained lipidic inclusions (Fig. 4C–E). We observed disturbed endoplasmic reticulum and Golgi apparatus, with dilatation and
fragmentation of channels and cisterns (Fig. 4C). The number of lysosomes was increased significantly, suggesting a high activation of the degradation processes. We encountered frequently axonal degenerative features, including axolemma decompactation (Fig. 4F–I).

In spinal cord dorsal and ventral columns, histological abnormalities not demonstrable at 12 months of age became evident in abcd2−/− mice at 20 months of age. Analysis of semithin sections showed fields of axonal spheroid degeneration comparable to those observed in abcd1−/− knock-out mice (21) (data not shown). Axonal degeneration and regeneration processes were often encountered in the form of axonal sprouting (Fig. 5A), consistent with findings of onion bulbs in sciatic nerve (Fig. 5B). Golgi apparatus fragmentation in the form of tubulo-vesicular inclusions was found in axons and neuronal cell bodies (Fig. 5C–E). Mitochondria abnormalities were frequent (Fig. 5E and G), as well as focal accumulation of organelles, a sign of disturbed axoplasmic flow (Fig. 5F). We then studied the dorsal columns of the spinal cord by immunohistochemical techniques. By Sudan black staining, we commonly evidenced axonal swellings (Fig. 6G and H), lesions that were often filled with ubiquitinated APP and synaptophysin accumulations, as revealed by analysis of serial sections (Fig. 6E–F and I–L). As a consequence, reactive astrogliosis appeared (Fig. 6A–D). The first signs of pathology were detected at 12 months in spinal cords and consisted on APP and synaptophysin accumulations in...
months of age, the abcd2–/– cerebellum showed no major changes in appearance of the molecular, Purkinje cell and granule cell layers, as well as normal foliation and cytarchitecture (data not shown). However, at 20 months of age, we detected gaps in the Purkinje cell monolayer in Nissl-stained sections (Fig. 7A and B). Immunohistochemistry against calbindin (D28-K) confirmed atrophy or death of Purkinje cells (Fig. 7C and D). A clear reduction of non-phosphorylated neurofilaments in Purkinje cells (SMI 32 antibody) (23) indicated reduced dendritic arborization (Fig. 7E and F). Fibrillar acidic protein (GFAP)-staining revealed an increased frequency of local spots of GFAP upregulation in the molecular layer of the cerebellum (Fig. 7E and F). These GFAP ‘hot-spots’ are likely to indicate a local degeneration of Purkinje cells with concomitant local reactive gliosis.

It is noteworthy that all the pathological changes noticed by ultrastructural or immunohistochemical techniques in abcd2–/– mice at DRGs, spinal cords and cerebellar sites were presented in the same extent, intensity and age by abcd1 deficient mice. Double mutants showed a more severe involvement and earlier onset of pathological signs, evidenced from 12 months onwards.

**DISCUSSION**

We present a model of late-onset, slowly progressive neuronal degeneration presumably caused by chronic accumulation of VLCFAs and/or other lipid metabolites due to ALDRP/ABCD2 inactivation.

On the basis of close sequence homology between abcd2/aldr and its paralog abcd1/ald, functional redundancy has been repeatedly suggested from the moment of its identification (24). Indeed, abcd2 is able to correct the VLCFAs accumulation due to abcd1 loss of function when over-expressed *in vitro* (15,16) and *in vivo* (18). In addition, over-expression of abcd3 corrects VLCFAs levels *in vitro*, although its inactivation in the mouse does not lead to VLCFAs accumulation (17). Similarly, we could not detect higher levels of VLCFAs in neural tissue of abcd2–/– mice (18), thus leaving open the question of the true role of abcd2 in relation to VLCFAs catabolism.

In the current work, we extended the biochemical analysis further to demonstrate a significant accumulation of VLCFAs in DRGs of abcd2–/– mice, together with normal levels of other peroxisomal metabolites. Thus, we present compelling evidence of a redundant biochemical function between the two transporters in the mouse. The normal levels of VLCFAs in brain and spinal cords of abcd2 mutants may be due to the fact that low numbers of DRGs express ALDRP (only one-fourth of the cells in total CNS homogenates are neurons, whereas 90% of the cells in DRGs are neurons), or alternatively, that its biochemical role regarding VLCFAs transport is quantitatively less important at the precise time point of analysis (8 months in whole neural tissue homogenates versus 5-day-old DRGs). It is worth noting that this biochemical abnormality in DRG neurons in abcd2–/– newborns correlates with a differential electromyographical phenotype against abcd1-deficient mice in adulthood. Indeed, ALD mice neither significantly

---

**Figure 6.** Gliosis, myelin and axonal pathology in spinal cord in abcd–/–. Longitudinal sections of the dorsal spinal cord in wild-type and abcd–/– and control littermates at the age of 20 months, processed for glial GFAP, lectin *L. esculentum*, APP, Sudan black and synaptophysin. (A–D) Reactive astrogliosis is observed in abcd–/– mice when compared with littermate controls. In (E and F), APP deposits are seen in axonal swellings in abcd–/– mice. This is accompanied by lipidic debris of myelin, as revealed with Sudan black in (G and H). In (I and J), abnormal fibers filled with synaptophysin are found in abcd–/– mice. Synaptophysin and APP deposits are ubiquitinated (K and L).
accumulated VLCFAs nor presented altered H-waves. The contrasting electromyographical phenotypes of abcd1- and abcd2−/− mice illustrate the complementary functions shared by the two transporters.

We face a different scenario when analyzing mouse fibroblasts. Most likely, because expression levels of abcd2 mRNA are rather low, inactivation of abcd2 neither leads to impairment of β-oxidation capacity nor to accumulation of VLCFAs. However, in a double mutant abcd1−/abcd2−/− context, accumulation of VLCFAs is significantly higher than in single abcd1- mutants, without additional impairment in peroxisomal degradation capacity. This might indicate that in this particular cell type and in the absence of ABCD1, ABCD2 is involved in a metabolic pathway other than degradation of VLCFAs, which leads to a secondary accumulation of VLCFAs. This is in agreement with results provided in McGuinness et al. (25), where the authors find normal VLCFAs β-oxidation levels in ALD mouse tissues and thus claim that the relationship between ALDP function and VLCFA metabolism is merely indirect.

Our findings demonstrate that loss of abcd1, the gene responsible for a demyelinating disease, leads to axonal degeneration, with degenerative features compatible with axonal transport impairment and to Purkinje cell loss in mice. This comes as no surprise if we consider that even in primary myelin disorders, such as multiple sclerosis (26), or

Figure 7. Cerebellar pathology in aldr−/− mice at 20 months of age. (B) Loss of Purkinje cell somata evidenced by Nissl staining (arrowheads). (D) Focal loss of staining with anti-calbindin D28K in the aldr−/− mice. (F) Focal upregulations of GFAP expression in aldr−/−. (H) Strong reduction of non-phosphorylated neurofilaments in Purkinje cells was seen by staining with anti-SMI32. (A, C, E and G) Images from wild-type littermate controls. Scale bar: 50 μm.
in the absence of a major myelin protein CPNase axonal loss occur (27). Those axonal swellings and degeneration have consequently been attributed to loss of oligodendroglia/myelin support. Thus, oligodendrocytes communicate in some way with the underlying axon and support axonal function. In contrast, inactivation of its predominantly neuronal expressed paralog abcd2 leads not only to the same type of phenotype, neuronal and axonal degeneration but also to astrocyte activation and gliosis. Along with these lines, at the histopathological level and by the means we have used, it has not been possible to clearly discriminate between the phenotypes of both mutants. Abcd1 and abcd2 deficient mice present very similar (in quality and quantity/number and morphology) accumulations of APP and synaptophysin in axonal swellings, astrogliosis in spinal cord and cerebellum and loss of Purkinje cells in cerebellum, despite the lack of detectable abnormalities in the cerebral cortex.

It is through neurological and electrophysiological testing that we can discriminate between the roles of both transporters. Abcd2−/− mice present defective spinal reflexes and ataxic phenotype, similar to the mouse models of Friedrich ataxia or vitamin E deficiency (28,29), at an age when Abcd1-mice still do well. The differences in expression pattern most likely account for a differential vulnerability/different target cellular populations, thus resulting in a different phenotypic outcome. Although abcd1 and abcd2 genes demonstrate functional redundancy that extends beyond their shared biochemical roles, abcd2−/− mice display abnormalities not observed in abcd1-mutant mouse, revealing that abcd1 and abcd2, or their genetic regulation, are not equivalent. For instance, the hyperactivity/lack of habituation phenotype displayed by aldr−/− mice deserves further study, as disturbance of higher cognitive functions could be underlying this pathological feature. Taking all pathological findings together, we conclude that abcd2−/− mice develop a late-onset spinocerebellar ataxia, with impaired proprioception most likely due to neuronal degenerative processes at the DRG level or to synaptic defects in spinal cord. To date, no human syndrome compatible with this phenotype has been linked to the ABCD2 locus at 12q1.1–1.2. Thus, description of the phenotype in mice might contribute to identifying patients suffering from a similar condition, i.e. an autosomal recessive peripheral neuropathy with cerebellar involvement, but without elevation of VLCFA in plasma or fibroblasts.

An interesting feature found in both ALD and ALDR mouse models is the presence of ultrastructural alterations of mitochondria in axons and neuronal bodies. The degradation of fatty acids in mammals takes place in mitochondria and peroxisomes. Very-long-chain and certain branched-chain fatty acids are first chain-shortened in peroxisomes, and subsequently, oxidized to completion in mitochondria via the β-oxidation pathway. A growing body of evidence suggests that mitochondria is playing a significant role in the pathogenesis of peroxisomal disease and that a relevant cross-talk connects both organelles. For instance, β-oxidation activity for VLCFAs is still present to ~60% in patients and mouse ALD-deficient fibroblasts (30–32); it is surprisingly normal in mouse tissues lacking ALDP (25) and even still present up to 20% in some cases in Zellweger patients fibroblasts (Wanders, personal communication). These findings are consistent with an overlapping or compensatory role between both organelles. Indeed, mitochondrial anomalies are observed in liver of mice with a total ablation of peroxisomal β-oxidation (inactivation of multifunctional proteins 1 and 2) (33). Moreover, functional and ultrastructural mitochondrial abnormalities have been found in the liver of a Zellweger syndrome mouse model (34,35), as well as in human Zellweger syndrome, including lipidic inclusions (36). Recently, the mitochondrion has also been implicated in the pathogenesis of X-ALD in mice and human. Lipidic intramitochondrial inclusions have been observed in atrophic neurons of DRG in patients with AMN, the adult form of X-ALD (37). Functional and structural alterations of mitochondria in adren cortex as a result of loss of ALDP are found in the X-ALD mouse model (25). These lipidic inclusions and condensation of cristae resemble the anomalies we have found in the neural tissue of both ALD and ALDR deficient mice. These signs of mitochondrial stress may reflect an attempt of the organelle to ‘back-up’ for the impaired peroxisomal function or simply an overload of the mitochondria with substrates that should have been degraded in peroxisomes. Defective mitochondria may lead to a failure of ATP-dependent axoplasmic transport with consequent ‘dying-back’ axonal degeneration. Indeed, structurally abnormal mitochondria in affected axons are associated with segmental axonal swelling and impairment of anterograde and retrograde transport in a mouse model of HSP (38). Mitochondrial damage has also been found associated with aberrant sprouting and synapse loss in AD and dementia with Lewy bodies (39). In our models, the presence of axonal swellings that accumulate neurofilaments and organelles suggests a similar pathogenetic mechanism. In addition, prominent in the ALD and ALDR mouse models is the tubulo-vesicular inclusions derived from endoplasmic reticulum and Golgi fragmentation. Interestingly, fragmentation of Golgi apparatus is found in sporadic amyotrophic lateral sclerosis (40,41) and in mouse models of tauopathies, where it has been associated with neuronal atrophy and non-apoptotic cell death (42). Thus, the neurodegenerative features we have identified in ALD and ALDR mouse models placed them in a common path with other major neurodegenerative diseases.

The link between defective VLCFAs catabolism and pathogenesis is not obvious in X-ALD. The incorporation of excess of VLCFAs into cell membranes might impair membrane stability (43) or perturb their microenvironment, resulting in dysfunction and death of vulnerable cells (44,45). Others showed that cells exposed to C26:0 produce higher levels of reactive oxygen species (46). While this article was in preparation, a direct correlation between accumulation of saturated VLCFAs in brain white matter and disease severity in human X-ALD patients has been reported, shedding some light into the issue (47). Thus, accumulation of VLCFAs in DRGs of abcd2−/− mice may increase the vulnerability to this particular cellular population to neurodegeneration. VLCFAs are found as lateral chains of complex lipids, such as phosphatidylycholine or phosphatidylethanolamine, thus playing a main structural role as components of cellular membranes. In neural membranes, a strict balance between free and esterified fatty acids is necessary, not only for normal membrane composition, integrity and function but also for the optimal
activity of the membrane-bound enzymes, receptors and ion channels involved in normal signal-transduction processes. We propose that the composition, maintenance or recycling process of myelin and neuronal/axonal membrane might be disturbed in the ALD and ALDR models, leading to impaired axono-glial communication, which would be detrimental for both interconnected compartments. Crucial to understanding of ALD and ALDR pathogenesis is to elucidate the mechanisms by which impaired peroxisomal function(s) or VLCFAs accumulation results in axonal degeneration, with features compatible with axonal transport impairment. VLCFAs levels have been found to be increased in X-ALD brain gangliosides (48), which might contribute to pathogenesis. Another plausible link may focus on the proteolipid protein (PLP/DM20), the main component of CNS myelin, accounting for >50% of the total protein of this membrane. PLP is a palmitoylated protein that contains mainly palmitic, oleic and stearic acids covalently bound as acyl chains. In adrenoleukodystrophy patients, the proportions of saturated VLCFAs bound to PLP have been found to be increased at the expense of oleic acid (49). Because covalently bound fatty acids contribute to the tertiary structure of PLP in aqueous medium (50), this altered fatty acid composition may influence its physical or biological properties, compromising stability of PLP itself or its insertion in the myelin sheath. Indeed, recent evidence indicates a severe impairment of fast axonal transport system in the PLP/DM20 deficient mouse (51), thus underscoring the importance of a healthy membrane for axonal function.

MATERIALS AND METHODS

Mouse generation, breeding and genotyping

The abcd2–/– mice were generated by inactivation of the abcd2 gene by classic homologous recombination. The abcd2 genomic sequence was isolated from a 129 mouse genomic library. Two fragments of the abcd2 gene were cloned into a pPNT backbone vector that contained a neomycin selection cassette flanked by LoxP sites (Fig. 1A). The linearized targeting vector was transfected into male R1 embryonic stem cells derived from 129 mouse strain. Double selection was performed with G418 and ganciclovir, and drug-resistant clones were screened for homologous recombination by Southern blotting (Fig. 1B). We obtained three recombinant clones, out of 302, resistant to neomycin, which were injected into blastocysts from C57BL/6 mice. Chimeric male pups were bred with C57BL/6 females to confirm germ-line transmission. DNA extracted from tails was used for PCR-based genotyping, using standard protocols. Primers used for genotyping were as follows: a common primer (5′-GAG CTagTGCTACGTTGCTG-3′) used together with a WT-specific (5′-TAAACCTGCTATTCTTACG-3′) or a KO-specific (5′-TGCAATTCATCTGTACGTAAG-3′) primer. The abcd1 gene inactivation has been described (30). To obtain double heterozygous mutants, we crossed abcd1+/− females with abcd2−/− mice. Double heterozygotes were intercrossed to obtain double knock-out mice and wild-type littermate controls; the offspring obeyed Mendelian ratios. Results described in this manuscript are derived from mice on a mixed C57BL/6J/129Sv background (~87% C57BL/6J and 13%129Sv).

Crucial experiments (locomotor tests and EMG) have been confirmed with pure C57BL/6J background mice. Histology, morphometric, behavioral testing and electrophysiological experiments were performed in a blind way with respect to the animal’s genotype. All methods employed in this work are in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publications no. 85-23, revised 1996).

Behavior tests

All experiments were performed with naive male animals, which were kept on a 12 h light/dark cycle.

Open field and rotarod tests

Coordination, balance and motor skill acquisition were tested using an accelerated rotating rod (Panlab, Barcelona, Spain) test, as described previously (21). In brief, mice were placed on the rod in a routine of four trials per day for a period of 4 days. The rod accelerated from 4 to 40 r.p.m. in 5 min and remained at maximum speed for 2 more minutes. Animals were scored for their latency to fall (in seconds) for each trial and rested a minimum of 10 min between trials to avoid exhaustion. Results were analyzed by a repeated-measure ANOVA test, considering three factors: days (fixed), genotype (fixed) and animals (variable), nested in genotype and crossed with days. Spontaneous ambulation in an open field was recorded during a 15 min period as described (21).

Horizontal bar cross test

The bar cross test is carried out using a wooden bar of 100 cm in length and 2 cm in width (diameter). This bar is just wide enough for mice to stand on with their hind feet hanging over the edge such that any slight lateral misstep will result in a slip. The bar is elevated 50 cm from the bench surface, so that animals do not jump off, yet are not injured upon falling from the bar. To eliminate the novelty of the tasks as a source of slips, all animals were given four trials on the bar at the beginning of the testing session. By the fourth trial, control animals ran the bar with not more than two slips. In the experimental session, the number of hind limb slips and falls from the bar and the time to reach the platform were counted on four consecutive trials. If an animal fell, it was placed back on the bar at the point at which it fell and was allowed to complete the task. The bar was cleaned with ethanol after each animal had crossed it.

Fibroblast culture and biochemical measurements

Primary fibroblast cultures were derived from mutant mice and their control littermates and grown at 37°C in 5% CO2 in DMEM, supplemented with fetal calf serum (10%), penicillin (100 U/ml) and streptomycin (100 U/ml). Cultures were grown to confluence on monolayer. Fatty acid β-oxidation was determined by measuring the capacity of the intact cells to degrade 141-C-labeled fatty acids (C26:0) to water-soluble products, essentially as described (52). Specific activity was expressed as picomoles of 14CO2 released per hour per
milligram of protein. Total cellular VLCFAs fatty acids were analyzed using electrospray ionization-tandem mass spectrometry (ESI-MS), as described recently (53). Branched-chain fatty acids in plasma and liver were analyzed using GC-MS (54). Total monounsaturated and polyunsaturated fatty acids in brain and plasmalogens in erythrocytes were measured by GC analysis (55).

Statistical analysis
Data are expressed as mean ± SD. Statistical significance was evaluated using ANOVA tests (Statview Package 5). The results were considered significant at $P < 0.01$.

Electrophysiological recordings
Electromyograms were performed at Neurofit (Strasbourg, France) using a Neuromatic 2000M apparatus (Dantec, Les Ulis, France). Mice were anesthetized with intraperitoneal injection of 60 mg/kg ketamine chlorohydrate (Imalgene Ulis, France) using a Neuromatic 2000M apparatus (Dantec, Les Ulis, France). Distal latency and amplitude of M- and H-waves were recorded in the plantar hind paw muscle after sciatic nerve stimulation.

Electron microscopy
Mice were anesthetized as described earlier and perfused with a 4% PFA and 3% glutaraldehyde (Fluka) in phosphate buffered (pH 7.4, 0.1 M) solution. Spinal cord, DRG and cerebrum were dissected and fixed overnight. Tissue was post-fixed for 1 h in 1% osmium tetroxide in phosphate buffer, dehydrated in serial ethanol solutions and embedded in an araldite–epon mixture. Embedded tissues were then placed at ± 60°C for 2 days to polymerize. Transverse semithin sections, 1 μm in thickness, were prepared with an ultramicrotome and stained with Toluidine blue. Ultrathin sections (50 nm) were investigated on a Philips C12-208 electron microscope at 80 kV.

In situ hybridization
ISH on mouse embryos (whole mounts) and radioactive ISH on post-natal frozen CNS were performed as described (56). The antisense RNA probes used contained the whole cDNA sequence of the abcd1 gene and the C-terminal half of the abcd2 gene, as previously described (19).

Immunohistochemistry
Mice were perfused with a 4% PFA solution. Spinal cords were embedded in paraffin and serial sections, 5 μm thick, were cut in the longitudinal plane with a sliding microtome. The sections were stained with hematoxylin and eosin, Luxol fast blue-Klüber-Barrera and Sudan black or processed for immunohistochemistry to glial GFAP (Dako, rabbit polyclonal, 1:500), ubiquitin (Dako, rabbit polyclonal, 1:500), APP (Boehringer, 1:10) and synaptophysin (Dako, monoclonal, 1:500). Lectin Lycopericon esculentum (Sigma, L-0651, 1:200) was used as a marker for microglial cells. The sections were incubated with the modified labeled streptavidin (LSAB) technique (DAKO LSAB2 System Peroxidase). The number of abnormal specific profiles was quantified in every tenth section for each particular stain. Five sections corresponding to the dorsal columns of the spinal cord were analyzed per animal and per stain. For analysis of the cerebellar pathology, frozen sections were used, which were incubated as free floating sections with antibodies against calbindin D28K (Swant, 1:1000), SM132 (Sternberger monoclonals, 1:1000) and GFAP (Dako, 1:1000). The staining was visualized with AlexaFluor 568 secondary antibodies (Molecular Probes).

ACKNOWLEDGEMENTS
We are indebted to Drs Deborah Bartholdi, Stéphane FOUR-cade, Sander Houten, Fredoen Valianpour, Marisa Girós, Montse Ruiz and Teresa Pampols for fruitful discussions. ALD mutant mice were a kind gift of Dr Kirby Smith (KKI, Baltimore, MD). We thank Sandra Metz for graphical work; C. Kretz, L. Reutenauer, J. Ruiter, H. Overmars, H. Rush, E. Vega, R. Blanco and M. Carmona for priceless technical assistance and Drs Marianne Lemeur, Elisabeth Metzger, Andrée Dierich and the staff at the IGBMC animal facility for mouse care. This study was supported by funds from the Institut National de la Santé et de la Recherche Médicale, the Centre National de la Recherche Scientifique, the European Commission contract no. LSHM-CT2004-502987, the Association Francaise contre les Myopathies (Grant no. 9315), the European Leukodystrophy Association and the Spanish Fondo de Investigacion Sanitaria (FIS, Ministerio de Sanidad project no. 01/1667).

Conflict of Interest statement. None declared.

REFERENCES


